{"id":"matched-placebo-for-primaquine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Matched-placebo formulations are used in clinical trials to maintain blinding while comparing the active drug (primaquine) against an inert control. Primaquine itself works by generating reactive oxygen species in parasitized cells, particularly targeting hypnozoites (dormant forms) in the liver and sexual-stage gametocytes in the blood. The matched placebo is designed to be indistinguishable from the active formulation in appearance, taste, and administration.","oneSentence":"This is a placebo control formulation matched to primaquine, an antimalarial drug that eliminates dormant liver-stage parasites and gametocytes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:11.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control arm in clinical trials of primaquine for malaria (likely P. vivax or P. ovale relapsing malaria)"}]},"trialDetails":[{"nctId":"NCT07468526","phase":"PHASE3","title":"An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06-01","conditions":"Malaria","enrollment":1019},{"nctId":"NCT02802501","phase":"PHASE3","title":"Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-08","conditions":"Malaria, Vivax","enrollment":150},{"nctId":"NCT02216123","phase":"PHASE3","title":"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-30","conditions":"Malaria, Vivax","enrollment":251},{"nctId":"NCT02788864","phase":"PHASE4","title":"Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2016-05-20","conditions":"Malaria","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matched-Placebo for Primaquine","genericName":"Matched-Placebo for Primaquine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation matched to primaquine, an antimalarial drug that eliminates dormant liver-stage parasites and gametocytes. Used for Placebo control arm in clinical trials of primaquine for malaria (likely P. vivax or P. ovale relapsing malaria).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}